



News Release

For Immediate Release
Lea Herzog, Marketing Manager
402-691-7444
lherzog@streck.com

Jan. 23, 2012

Streck adds CD38 to flow cytometry controls

Omaha, NE – Streck has added CD38 to its flow cytometry controls, CD-Chex[®] Plus and CD-Chex[®] Plus BC.

Along with other assayed CD markers, CD38 is often used by laboratories as a prognostic marker for leukemia. Provided assayed values save the lab time by providing established means and ranges for these CD markers.

CD-Chex Plus and CD-Chex Plus BC are whole blood assayed controls for monitoring immunophenotyping by flow cytometry. These products verify the accuracy and reproducibility of all the steps involved in the process of immunophenotyping, including red blood cell lysis. The products provide the most assayed CD markers in the industry, which include: T lymphocytes, B lymphocytes, granulocytes, monocytes and NK cells. CD-Chex Plus CD4 Low and CD-Chex Plus BC CD4 Low offer a depressed CD4 absolute number often indicated in patients with immunodeficiency diseases.

Compatible with most popular flow cytometry systems, CD-Chex Plus and CD-Chex Plus BC are available in 3.0ml plastic vials with pierceable caps and offer 30-day open-vial stability and up to 90-day closed-vial stability.

Streck offers a free Interlaboratory Quality Control program for all customers and has electronic data entry forms for customers who utilize CD-Chex Plus and CD-Chex Plus BC. The electronic *STATS*[®] forms facilitate data tracking and submission.

About Streck, Inc.

Streck is a leading independent developer and manufacturer of products for the clinical and research laboratory. Over the past 40 years, Streck has developed a reputation for excellence that includes consistent, high-quality controls and responsive customer service and technical service teams. For more information, call 800-843-0912 or consult Streck online at www.streck.com.